These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 27520857

  • 1. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
    Refaat R, Sakr A, Salama M, El Sarha A.
    Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857
    [Abstract] [Full Text] [Related]

  • 2. Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
    Khan S, Khan S, Panda BP, Akhtar M, Najmi AK.
    Expert Opin Ther Targets; 2015 Sep; 19(12):1607-16. PubMed ID: 26357866
    [Abstract] [Full Text] [Related]

  • 3. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Sharma AK, Kanawat DS, Mishra A, Dhakad PK, Sharma P, Srivastava V, Joshi S, Joshi M, Raikwar SK, Kurmi MK, Srinivasan BP.
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D, He YL, Bullock J, Riviere GJ, Balez S, Schwartz S, Wang Y, Ligueros-Saylan M, Jarugula V, Dole WP.
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [Abstract] [Full Text] [Related]

  • 5. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA.
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [Abstract] [Full Text] [Related]

  • 6. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats.
    Akarte AS, Srinivasan BP, Gandhi S, Sole S.
    Eur J Pharm Sci; 2012 Sep 29; 47(2):456-63. PubMed ID: 22800967
    [Abstract] [Full Text] [Related]

  • 7. Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway.
    Aldakinah AA, Al-Shorbagy MY, Abdallah DM, El-Abhar HS.
    J Pharm Pharmacol; 2017 Jul 29; 69(7):856-864. PubMed ID: 28271502
    [Abstract] [Full Text] [Related]

  • 8. Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
    Eom YS, Gwon AR, Kwak KM, Kim JY, Yu SH, Lee S, Kim YS, Park IB, Kim KW, Lee K, Kim BJ.
    PLoS One; 2016 Jul 29; 11(12):e0168569. PubMed ID: 27997588
    [Abstract] [Full Text] [Related]

  • 9. Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
    Abdelhamid AM, Abdelaziz RR, Salem HAA.
    Can J Physiol Pharmacol; 2018 Aug 29; 96(8):710-718. PubMed ID: 29510081
    [Abstract] [Full Text] [Related]

  • 10. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
    El Batsh MM, El Batch MM, Shafik NM, Younos IH.
    Eur J Pharmacol; 2015 Dec 15; 769():297-305. PubMed ID: 26607467
    [Abstract] [Full Text] [Related]

  • 11. Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
    Tawfik MK.
    Eur Rev Med Pharmacol Sci; 2012 May 15; 16(5):600-9. PubMed ID: 22774400
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
    Baig MMFA, Khan S, Naeem MA, Khan GJ, Ansari MT.
    Biomed Pharmacother; 2018 Jan 15; 97():1250-1258. PubMed ID: 29145151
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L, Araújo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, Silva ME, de Lima WG, Costa DC.
    Arch Med Res; 2013 Apr 15; 44(3):194-202. PubMed ID: 23523961
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.
    Diabetes Obes Metab; 2007 Mar 15; 9(2):175-85. PubMed ID: 17300593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.